<DOC>
	<DOCNO>NCT00109187</DOCNO>
	<brief_summary>This Phase IIIb , multicenter , open-label , extension study available subject successfully complete Study Q2143g participate Study Q2195g . Subjects register via IVRS ( Interactive Voice Response System ) within 48 hour prior baseline visit . All subject study treat Xolair 24 week . Subjects New Treatment Group may require additional visit study drug injection ( frequently every 2 week ) . Data collection additional visit limit assessment adverse event . The study evaluate serious nonserious adverse event , laboratory assessment , data asthma exacerbation , concomitant medication usage .</brief_summary>
	<brief_title>An Extension Study Xolair Moderate Severe , Persistent Asthma Patients Who Completed Study Q2143g</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Successful completion 24week study period Study Q2143g Signed inform consent ( case minor , consent must give child 's parent legally authorize representative ) For subject never receive Xolair , serum IgE level &gt; =30 IU/mL &lt; =1300 IU/mL body weight &gt; =20 kg &lt; =150 kg Females childbearing potential must , opinion investigator , use effective method contraception prevent pregnancy agree continue practice acceptable method contraception duration participation study . Thrombocytopenia evidence platelet count &lt; 100,000/uL Pregnant breastfeeding Significant systemic disease ( e.g. , infection , hematologic , renal , hepatic , coronary heart disease cardiovascular disease , endocrine gastrointestinal disease ) within previous 3 month History neoplasia Any systemic condition require regular administration immunoglobulin Known hypersensitivity ingredient Xolair , include excipients ( sucrose , histidine , polysorbate 20 ) History noncompliance medical regimen Current participation study use investigational new drug Xolair Participation Study Q2195g</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Moderate Persistent Asthma</keyword>
	<keyword>Severe Persistent Asthma</keyword>
</DOC>